Literature DB >> 16988455

Prime-boost strategies in DNA vaccines.

C Jane Dale1, Scott Thomson, Robert De Rose, Charani Ranasinghe, C Jill Medveczky, Joko Pamungkas, David B Boyle, Ian A Ramshaw, Stephen J Kent.   

Abstract

Induction of HIV-specific T-cell responses by vaccines may facilitate efficient control of HIV replication. Plasmid DNA vaccines and recombinant fowlpox virus (rFPV) vaccines are promising HIV-1 vaccine candidates, although delivering either vaccine alone may be insufficient to induce sufficient T-cell responses. A consecutive immunization strategy, known as "prime-boost," involving priming with DNA and boosting with rFPV vaccines encoding multiple common HIV antigens, is used to induce broad and high-level T-cell immunity and ameliorate AIDS in macaques. This vaccine strategy is proceeding to clinical trials. This chapter describes the use of prime-boost vaccines to induce T-cell responses against HIV-1 and protective immunity against AIDS in macaques. Methods for the construction of the vaccines, the use of animal models, and the detection of immune responses are described.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988455     DOI: 10.1385/1-59745-168-1:171

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  16 in total

Review 1.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

2.  Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.

Authors:  Antonio Valentin; Agneta von Gegerfelt; Margherita Rosati; Georgios Miteloudis; Candido Alicea; Cristina Bergamaschi; Rashmi Jalah; Vainav Patel; Amir S Khan; Ruxandra Draghia-Akli; George N Pavlakis; Barbara K Felber
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

3.  Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Authors:  Josephine H Cox; Maria G Ferrari; Patricia Earl; James R Lane; Linda L Jagodzinski; Victoria R Polonis; Ellen G Kuta; Jean D Boyer; Silvia Ratto-Kim; Leigh-Anne Eller; Doan-Trang Pham; Lydia Hart; David Montefiori; Guido Ferrari; Stephanie Parrish; David B Weiner; Bernard Moss; Jerome H Kim; Deborah Birx; Thomas C VanCott
Journal:  Vaccine       Date:  2012-01-09       Impact factor: 3.641

4.  A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.

Authors:  Lan Chen; Dan Ewing; Hemavathy Subramanian; Karla Block; Jonathan Rayner; Kimberly D Alterson; Martha Sedegah; Curtis Hayes; Kevin Porter; Kanakatte Raviprakash
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 5.  Cancer vaccines: translation from mice to human clinical trials.

Authors:  Hoyoung Maeng; Masaki Terabe; Jay A Berzofsky
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

6.  Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Authors:  Janet L Brandsma; Mark Shlyankevich; Yuhua Su; Daniel Zelterman; John K Rose; Linda Buonocore
Journal:  Vaccine       Date:  2009-07-15       Impact factor: 3.641

7.  Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.

Authors:  Igor M Belyakov; Jeffrey D Ahlers; Gary J Nabel; Bernard Moss; Jay A Berzofsky
Journal:  Virology       Date:  2008-09-14       Impact factor: 3.616

8.  Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation.

Authors:  Margherita Rosati; Antonio Valentin; Rashmi Jalah; Vainav Patel; Agneta von Gegerfelt; Cristina Bergamaschi; Candido Alicea; Deborah Weiss; Jim Treece; Ranajit Pal; Phillip D Markham; Ernesto T A Marques; J Thomas August; Amir Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2008-04-21       Impact factor: 3.641

9.  Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.

Authors:  Adebayo J Molehin; Souad R Sennoune; Weidong Zhang; Juan U Rojo; Arif J Siddiqui; Karlie A Herrera; Laura Johnson; Justin Sudduth; Jordan May; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2017-10-12       Impact factor: 2.289

10.  Role of novel type I interferon epsilon in viral infection and mucosal immunity.

Authors:  Yang Xi; Stephanie L Day; Ronald J Jackson; Charani Ranasinghe
Journal:  Mucosal Immunol       Date:  2012-05-23       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.